UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Role of Autophagy in Multiple Myeloma Progression

Blood, 2017-12, Vol.130, p.5355-5355

2017

Volltextzugriff (PDF)

Cell Free MYC DNA Copy Number Identifies High-Risk Smouldering Myeloma and Newly Diagnosed Multiple Myeloma

Blood, 2023-11, Vol.142 (Supplement 1), p.878-878

2023

Volltextzugriff (PDF)

Evaluation of Easym, a Clonotypic Mass Spectrometry Assay, and Euroflow Minimal Residual Disease Assessment in Multiple Myeloma

Blood, 2023-11, Vol.142 (Supplement 1), p.3328-3328

2023

Volltextzugriff (PDF)

Overcoming Innate Resistance to a Beta-Catenin Inhibitor-BC2059- By Manipulating Autophagy in Multiple Myeloma

Blood, 2016-12, Vol.128 (22), p.5669-5669

2016

Volltextzugriff (PDF)

In Vitro and In Vivo Efficacy of a Novel Orally Bioavailable Beta-Catenin Inhibitor-BC2059- As Monotherapy or in Combination with Proteasome Inhibitors in Multiple Myeloma

Blood, 2015-12, Vol.126 (23), p.1816-1816

2015

Volltextzugriff (PDF)

Identification of Acetylation, Immune Cell Alterations and Gene Signature As Dynamic Biomarkers of Response to Panobinostat Treatment in Multiple Myeloma Patients

Blood, 2017-12, Vol.130, p.1823-1823

2017

Volltextzugriff (PDF)

TOP2A Knockdown Resensitizes Carfilzomib-Resistant Hmcls to Carfilzomib

Blood, 2015-12, Vol.126 (23), p.4215-4215

2015

Volltextzugriff (PDF)

BC2059: An Orally Bioavailable β-Catenin Inhibitor Potently Induces Apoptosis As A Single Agent and In Combination With Bortezomib In Multiple Myeloma

Blood, 2013-11, Vol.122 (21), p.1920-1920

2013

Volltextzugriff (PDF)

A 2-Stage Phase II Study of Panobinostat Consolidation in Multiple Myeloma (MM) Patients with < CR Following Single High-Dose Chemotherapy (HDT) Conditioned Autologous Stem Cell Transplantation (ASCT) As Part of First Line Therapy

Blood, 2016-12, Vol.128 (22), p.4515-4515

2016

Volltextzugriff (PDF)

Roar: A Phase Ib Trial of Oral Azacitidine in Combination with Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma (MM) Patients Refractory to Prior Lenalidomide

Blood, 2015-12, Vol.126 (23), p.3033-3033

2015

Volltextzugriff (PDF)

CD45-Ve but Not CD45+Ve U266 Myeloma Cells Demonstrate an Active Epithelial to Mesenchymal Transition (EMT) Transcriptional Programme

Blood, 2012-11, Vol.120 (21), p.3988-3988

2012

Volltextzugriff (PDF)

Targeting the Wnt/Beta-Catenin Pathway in Multiple Myeloma with a Novel Orally Bioavailable Beta-Catenin Inhibitor

Blood, 2012-11, Vol.120 (21), p.1842-1842

2012

Volltextzugriff (PDF)

Roar: A Phase Ib Trial of Oral Azacitidine (CC-486) in Combination with Lenalidomide and Dexamethasone (Rd) for Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma Who Have Failed a Prior Lenalidomide-Containing Regimen

Blood, 2016-12, Vol.128 (22), p.2121-2121

2016

Volltextzugriff (PDF)

A Newly Developed IAP Inhibitor (IAPi) Induces Apoptosis of Human Myeloma Cells and Synergises with Conventional and Novel Anti-Myeloma Therapeutics

Blood, 2008-11, Vol.112 (11), p.5156-5156

2008

Volltextzugriff (PDF)

Abstract 4579: The novel MEK Inhibitor GSK1120212b inhibits HMCL growth in vitro and synergises with a range of conventional and novel anti-myeloma therapies

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.4579-4579

2012

Volltextzugriff (PDF)

The Anti-Kappa Monoclonal Antibody MDX-1097 Synergizes with Immunomodulatory Drugs to Enhance Antibody-Dependent Cell Cytotoxicity of Multiple Myeloma Cells

Blood, 2012-11, Vol.120 (21), p.4012-4012

2012

Volltextzugriff (PDF)

Evaluation of Circulating Tumour DNA for the Mutational Characterisation of Multiple Myeloma

Blood, 2015-12, Vol.126 (23), p.368-368

2015

Volltextzugriff (PDF)

Leopard: A Phase II Study of Maintenance Lenalidomide and Prednisolone Post Autologous Stem Cell Transplantation (ASCT) for Myeloma, Incorporating Minimal Residual Disease Assessments

Blood, 2014-12, Vol.124 (21), p.2103-2103

2014

Volltextzugriff (PDF)

A Novel Orally Bioavailable Heat Shock Protein 90 Inhibitor Induces Apoptosis and Synergises with Bortezomib in Human Multiple Myeloma

Blood, 2009-11, Vol.114 (22), p.1838-1838

2009

Volltextzugriff (PDF)

Leopard: A Phase II Study Of Post Autologous Stem Cell Transplantation (ASCT) Maintenance Lenalidomide and Prednisolone For Myeloma (MM), Incorporating Minimal Residual Disease (MRD) Assessments

Blood, 2013-11, Vol.122 (21), p.3223-3223

2013

Volltextzugriff (PDF)

Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma

Epigenetics, 2014-11, Vol.9 (11), p.1511-1520

2014

Volltextzugriff (PDF)

Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma

Molecular cancer therapeutics, 2011-10, Vol.10 (10), p.1909-1917

2011

Volltextzugriff (PDF)

Circulating Tumour DNA Analysis for Tumour Genome Characterisation and Monitoring Disease Burden in Extramedullary Multiple Myeloma

International journal of molecular sciences, 2018-07, Vol.19 (7), p.1858

2018

Volltextzugriff (PDF)

MCL-1 Inhibitor-Induced Killing of Multiple Myeloma Is Modulated By the Relative Level of Expression of Pro-Survival Members of the BCL-2 Family and the Proto-Oncogene MYC

Blood, 2019-11, Vol.134 (Supplement_1), p.1825-1825

2019

Volltextzugriff (PDF)

Translational Potential of RNA Derived From Extracellular Vesicles in Multiple Myeloma

Frontiers in oncology, 2021-08, Vol.11, p.718502-718502

2021

Volltextzugriff (PDF)

1 – 25 von 108

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(104)
Mit Volltextzugriff
(97)

Publikationsform

Sprache

Englisch
(108)

Erscheinungsjahr

n.n

Thema

Science & Technology
(40)
Life Sciences & Biomedicine
(37)
Humans
(27)
Multiple Myeloma
(20)
Hematology
(18)
Oncology
(16)
Cell Line, Tumor
(10)
Multiple Myeloma - Drug Therapy
(10)
Multiple Myeloma - Pathology
(8)
Tumors
(8)
Male
(7)
Patients
(7)
Apoptosis - Drug Effects
(6)
Biomarkers
(6)
Bone Marrow
(6)
Cancer
(6)
Female
(6)
Multiple Myeloma - Genetics
(6)
Animals
(5)
Antineoplastic Agents - Pharmacology
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The Role of Autophagy in Multiple Myeloma Progression

Cell Free MYC DNA Copy Number Identifies High-Risk Smouldering Myeloma and Newly Diagnosed Multiple Myeloma

Evaluation of Easym, a Clonotypic Mass Spectrometry Assay, and Euroflow Minimal Residual Disease Assessment in Multiple Myeloma

Overcoming Innate Resistance to a Beta-Catenin Inhibitor-BC2059- By Manipulating Autophagy in Multiple Myeloma

In Vitro and In Vivo Efficacy of a Novel Orally Bioavailable Beta-Catenin Inhibitor-BC2059- As Monotherapy or in Combination with Proteasome Inhibitors in Multiple Myeloma

Identification of Acetylation, Immune Cell Alterations and Gene Signature As Dynamic Biomarkers of Response to Panobinostat Treatment in Multiple Myeloma Patients

TOP2A Knockdown Resensitizes Carfilzomib-Resistant Hmcls to Carfilzomib

BC2059: An Orally Bioavailable β-Catenin Inhibitor Potently Induces Apoptosis As A Single Agent and In Combination With Bortezomib In Multiple Myeloma

A 2-Stage Phase II Study of Panobinostat Consolidation in Multiple Myeloma (MM) Patients with < CR Following Single High-Dose Chemotherapy (HDT) Conditioned Autologous Stem Cell Transplantation (ASCT) As Part of First Line Therapy

Roar: A Phase Ib Trial of Oral Azacitidine in Combination with Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma (MM) Patients Refractory to Prior Lenalidomide

CD45-Ve but Not CD45+Ve U266 Myeloma Cells Demonstrate an Active Epithelial to Mesenchymal Transition (EMT) Transcriptional Programme

Targeting the Wnt/Beta-Catenin Pathway in Multiple Myeloma with a Novel Orally Bioavailable Beta-Catenin Inhibitor

Roar: A Phase Ib Trial of Oral Azacitidine (CC-486) in Combination with Lenalidomide and Dexamethasone (Rd) for Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma Who Have Failed a Prior Lenalidomide-Containing Regimen

A Newly Developed IAP Inhibitor (IAPi) Induces Apoptosis of Human Myeloma Cells and Synergises with Conventional and Novel Anti-Myeloma Therapeutics

Abstract 4579: The novel MEK Inhibitor GSK1120212b inhibits HMCL growth in vitro and synergises with a range of conventional and novel anti-myeloma therapies

The Anti-Kappa Monoclonal Antibody MDX-1097 Synergizes with Immunomodulatory Drugs to Enhance Antibody-Dependent Cell Cytotoxicity of Multiple Myeloma Cells

Evaluation of Circulating Tumour DNA for the Mutational Characterisation of Multiple Myeloma

Leopard: A Phase II Study of Maintenance Lenalidomide and Prednisolone Post Autologous Stem Cell Transplantation (ASCT) for Myeloma, Incorporating Minimal Residual Disease Assessments

A Novel Orally Bioavailable Heat Shock Protein 90 Inhibitor Induces Apoptosis and Synergises with Bortezomib in Human Multiple Myeloma

Leopard: A Phase II Study Of Post Autologous Stem Cell Transplantation (ASCT) Maintenance Lenalidomide and Prednisolone For Myeloma (MM), Incorporating Minimal Residual Disease (MRD) Assessments

Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma

Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma

Circulating Tumour DNA Analysis for Tumour Genome Characterisation and Monitoring Disease Burden in Extramedullary Multiple Myeloma

MCL-1 Inhibitor-Induced Killing of Multiple Myeloma Is Modulated By the Relative Level of Expression of Pro-Survival Members of the BCL-2 Family and the Proto-Oncogene MYC

Translational Potential of RNA Derived From Extracellular Vesicles in Multiple Myeloma

Suchergebnisse filtern